Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 5/20 | 0.37 |
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 5/20 | 0.36 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | DRD5 | P21918 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.35 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.35 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.35 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.35 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.35 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.35 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073380 | 0.85 | KDM1A (0.46) | MAOBMAOAKDM1ANISCHALDH1A1 | |
| SCHEMBL878092 | 0.82 | RECQL (0.34) | NISCHKDM4EMAPTHSD17B10ALDH1A1 | |
| SCHEMBL240623 | 0.81 | ADCY5 (0.38) | NISCHMAPTADCY5 | |
| SCHEMBL10520604 | 0.81 | TAAR1 (0.39) | TAAR1MAOBKDM1AMAPTCYP3A4 | |
| SCHEMBL1616732 | 0.81 | KDM1A (0.38) | KDM1ATDP1 | |
| SCHEMBL9375602 | 0.81 | CYP19A1 (0.33) | — | |
| SCHEMBL595524 | 0.81 | HTR3A (0.50) | TAAR1 | |
| SCHEMBL1461219 | 0.80 | CHRNB2 (0.50) | KDM1ACYP2C9 | |
| SCHEMBL1254610 | 0.79 | SLC6A3 (0.44) | TAAR1MAPT | |
| SCHEMBL3666428 | 0.79 | TAAR1 (0.44) | TAAR1NISCHNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 976 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184965-A | Polyimide-based polymer, and preparation method and application thereof | 华南师范大学 | 2024-06-14 | — | — | CN | claimed |
| CN-117586233-A | Preparation and application of N- [ (1H-indol-4-yl) alkyl ] benzamide compound | 沈阳药科大学 | 2024-02-23 | — | — | CN | claimed |
| CN-117298148-A | Application of aminodithioformate compound or pharmaceutically acceptable salt thereof in combination with copper ions in preparation of antitumor drugs | 北京大学 | 2023-12-29 | — | — | CN | claimed |
| CN-114751858-B | Quinolinyl-containing tranexamic acid derivative and preparation and application thereof | 沈阳药科大学 | 2023-09-12 | — | — | CN | claimed |
| EP-4100393-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2022-12-14 | — | — | EP | claimed |
| CN-114773267-A | [ (7-trifluoromethyl quinoline-4-yl) amino ] benzamide compound and preparation and application thereof | 沈阳药科大学 | 2022-07-22 | — | — | CN | claimed |
| CN-114751858-A | Quinolinyl-containing tranexamic acid derivative, preparation and application thereof | 沈阳药科大学 | 2022-07-15 | — | — | CN | claimed |
| US-20220128562-A1 | BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF | UNIVERSITY OF KANSAS | 2022-04-28 | — | — | US | claimed |
| CN-110003176-B | Amide-containing benzimidazole compound and application thereof | 沈阳药科大学 | 2021-12-21 | — | — | CN | claimed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | claimed |
| EP-0175650-A2 | Benzazoles, process for their preparation, pharmaceutical compositions containing them and their use | CIBA-GEIGY AG (CH) | 1986-03-26 | — | — | EP | claimed |
| EP-0158278-A2 | Oxindole compounds for use against epilepsy | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-10-16 | — | — | EP | claimed |
| US-4472400-A | Triazoloquinazolones having antihistaminic and bronchospasmolytic activity | ROUSSEL UCLAF (FR) | 1984-09-18 | — | — | US | claimed |
| EP-0076199-A2 | Triazoloquinazolones and their salts, process and intermediates for preparing them, their use as medicines and compositions containing them | ROUSSEL-UCLAF (FR) | 1983-04-06 | — | — | EP | claimed |
| US-4192874-A | Substituted 1,2,6,7-tetrahydroindolo[1,7-ab][1,5]benzodiazepines | AMERICAN HOECHST CORPORATION (US) | 1980-03-11 | — | — | US | claimed |
| US-4154727-A | REACTING A GLYCINAMIDE WITH A HALOACETYL HALIDE | SHIONOGI & CO., LTD. (JP) | 1979-05-15 | — | — | US | claimed |
| US-4107437-A | SEDATIVES, ANTIARRHYTHMIA AGENTS | PARCOR (FR) | 1978-08-15 | — | — | US | claimed |
| US-4081444-A | Phenylpiperazinotetrahydronaphthols and derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-03-28 | — | — | US | claimed |
| US-4018773-A | Phenylpiperazinotetrahydronaphthols and derivatives | E. R. SQUIBB & SONS, INC. (US) | 1977-04-19 | — | — | US | claimed |
| US-3953469-A | TRANQUILLIZERS | E. R. SQUIBB & SONS, INC. (US) | 1976-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220128562-A1 | BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF | NQO1, KEAP1, NFE2L2 | SLC18A3 4505/4885SIGMAR1 4577/4885TAAR1 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.